Listing of Claims:

Please **amend** the claims as follows:

Claim 1 **(Previously Presented)** An isolated polynucleotide, comprising a polynucleotide sequence which codes without interruption for human Urb-ctf comprising amino acids 1-614 as set forth in SEQ ID NO 2, or a complete complement thereto.

Claim 2 **(Currently amended)** An isolated polynucleotide of claim 1, comprising the polynucleotide sequence from nucleotide positions ~~18-1919~~ 78-1922 as set forth in SEQ ID NO 1, or a complete complement thereto.

Claim 3 **(Currently amended)** An isolated human polynucleotide, comprising a polynucleotide sequence ~~having 97% or more nucleotide sequence identity along its entire length to the polynucleotide sequence set forth in SEQ ID NO 1,~~ which codes without interruption for a full-length human Urb-ctf having 614 amino acids, which has transcriptional regulatory activity, and ~~which is up-regulated in a human breast cancer~~ which hybridizes to the complete complement of SEQ ID NO: 1 ~~, wherein said polynucleotide hybridizes~~ under high stringency conditions comprising overnight incubation in 5X SSC, 0.5% SDS, 100 μg/ml denatured salmon sperm DNA and 50% formamide, at 42°C, followed by washing in 0.1% SSC and 0.1% SDS for 30 min at 65°C ~~to the complete complement of the sequence set forth in SEQ ID NO:1~~.

Claim 4 **(Cancelled)**

Claim 5 **(Current amended)** An isolated polynucleotide consisting of ~~comprising~~ a polynucleotide sequence selected from SEQ ID NO 1 ~~which is specific for human Urb-ctf~~ and which codes for a polypeptide fragment of SEQ ID NO:2, said polynucleotide comprising the position which corresponds to

amino acid 38 of SEQ ID NO 2,
amino acid 68 of SEQ ID NO 2,
amino acids 76-77 of SEQ ID NO 2,
amino acid 119 of SEQ ID NO 2,
amino acid 143-144 of SEQ ID NO 2,
amino acid 161 of SEQ ID NO 2,
amino acid 583 of SEQ ID NO 2,
amino acid 606 of SEQ ID NO 2, or
complete complements thereof.

Claim 6 **(Currently amended)** An isolated polynucleotide of claim 5, ~~comprising~~ which is a polynucleotide coding for amino acids 1-263 of SEQ ID NO 2 or 459-614 of SEQ ID NO 2, or a complete complement thereof.

Claim 7 **(Previously Presented)** An isolated polynucleotide of claim 5, wherein said polynucleotide is effective as a primer in a polymerase chain reaction.

Claim 8 **(Original)** An isolated polynucleotide of claim 5, which codes for a polypeptide comprising at least eight amino acids in length.

Claim 9 **(Original)** An isolated human Urb-ctf polypeptide of claim 1 comprising, the amino acid sequence set forth in SEQ ID NO 2.

Claim 10 (Original) An isolated human Urb-ctf polypeptide of claim 3 comprising, an amino acid sequence having 99% or more sequence identity to the amino acid sequence set forth in SEQ ID NO 2.

Claim 11 (Original) An isolated human Urb-ctf polypeptide of claim 10, which has transcriptional regulatory activity.

Claim 12 (Original) An isolated human polypeptide which is specific for Urb-ctf of claim 8, said polypeptide comprising:

amino acid 38 of SEQ ID NO 2,
amino acid 68 of SEQ ID NO 2,
amino acids 76-77 of SEQ ID NO 2,
amino acid 119 of SEQ ID NO 2,
amino acid 143-144 of SEQ ID NO 2,
amino acid 161 of SEQ ID NO 2,
amino acid 583 of SEQ ID NO 2, or
amino acid 606 of SEQ ID NO 2.

Claim 13 (Original) An isolated polypeptide of claim 12, comprising, a polypeptide coding for amino acids 1-263 of SEQ ID NO 2 or 459-614 of SEQ ID NO 2.

Claim 14 (Original) A method of treating breast cancer showing altered expression of human Urb-ctf of claim 1, comprising:
administering to a subject in need thereof a therapeutic agent which is effective for regulating expression of said Urb-ctf gene or polypeptide.

Claim 15 (Original) A method of claim 14, wherein said agent is an antisense which is effective to inhibit translation of the gene coding for human Urb-ctf.

Claim 16 (Original) A method of diagnosing human breast cancer disease associated with abnormal Urb-ctf expression , or determining a subject's susceptibility to such disease, comprising:

assessing the expression of human Urb-ctf of claim 1 in a tissue sample comprising breast cancer cells.

Claim 17 (Original) A method of claim 16, wherein assessing is:

measuring expression levels of said gene, determining the genomic structure of said gene, determining the mRNA structure of transcripts from said gene, or measuring the expression levels of polypeptide coded for by said gene.

Claim 18 (Original) A method of claim 16, wherein said assessing detecting is performed by:

Northern blot analysis, polymerase chain reaction (PCR), reverse transcriptase PCR, RACE PCR, or *in situ* hybridization, and

using a polynucleotide probe having a sequence selected from SEQ ID NO 1, a polynucleotide having 99% sequence identity or more to a sequence set forth in SEQ ID NO 1, or complements thereto.

Claim 19 (Original) A method of assessing a therapeutic or preventative intervention in a human subject having breast cancer, comprising,

determining the expression levels of human Urb-ctf of claim 1 in a tissue sample comprising breast cancer cells, or cells derived from breast cancer.

Claim 20 (Original) A method for identifying an agent that modulates the expression of human Urb-ctf of claim 1 in cells, comprising,

contacting a cell population with a test agent under conditions effective for said test agent to modulate the expression of the gene coding for human Urb-ctf in cells, and

determining whether said test agent modulates said gene.

Claim 21 (Original) A method of claim 20, wherein said agent is an antisense polynucleotide to a target polynucleotide sequence selected from SEQ ID NO 1 and which is effective to inhibit translation of said gene.

Claim 22 (Original) A method for identifying an agent that modulates the biological activity of human Urb-ctf of claim 8, comprising,

contacting human Urb-ctf polypeptide of claim 8 with a test agent under conditions effective for said test agent to modulate the biological activity of said polypeptide, and

determining whether said test agent modulates said polypeptide.

Claim 23 (Original) A non-human, transgenic mammal whose genome comprises a recombinant polynucleotide coding for a human Urb-ctf of claim 1 operatively linked to an expression control sequence effective to express said gene in breast tissue.

Claim 24 (Original) A non-human transgenic mammal of claim 22, wherein said expression control sequence is an inducible promoter.

Claim 25 (Original) An antibody which is specific for human Urb-ctf of claim 1, which antibody is specific for an epitope comprising:

amino acid 38 of SEQ ID NO 2,

amino acid 68 of SEQ ID NO 2,
amino acids 76-77 of SEQ ID NO 2,
amino acid 119 of SEQ ID NO 2,
amino acid 143-144 of SEQ ID NO 2,
amino acid 161 of SEQ ID NO 2,
amino acid 583 of SEQ ID NO 2, or
amino acid 606 of SEQ ID NO 2.

Claim 26 (Original) A method of advertising human Urb-ctf of claim 1 for sale, commercial use, or licensing, comprising,

displaying in a computer-readable medium a polynucleotide sequence set forth in SEQ ID NO 1, or complements thereto, or a polypeptide sequence set forth in sequence in SEQ ID NO 2.

Claim 27 (Original) A method of selecting a breast cancer marker from a database comprising polynucleotide sequences, comprising

displaying, in a computer-readable medium, a polynucleotide sequence or polypeptide sequence for human Urb-ctf of claim 1, or complements to the polynucleotides sequence, wherein said displayed sequences have been retrieved from said database upon selection by a user.

Claim 28 (Previously Presented) An isolated polynucleotide of claim 1, comprising the polynucleotide sequence from nucleotide positions 1-4372 as set forth in SEQ ID NO 1, or a complete complement thereto.

Claim 29 (Previously Presented) An isolated polynucleotide of claim 5, which comprises at least 15 nucleotides.

Claim 30 (Previously Presented) An isolated polynucleotide of claim 5, which comprises at least 24 nucleotides.

Claim 31 (Previously Presented) An isolated polynucleotide of claim 5, which comprises at least 30 nucleotides.

Claim 32 (Previously Presented) An isolated polynucleotide of claim 5, which comprises at least 45 nucleotides.